Schmidli R S, Colman P G, Bonifacio E, Bottazzo G F, Harrison L C
Endocrinology Laboratory, Royal Melbourne Hospital, Australia.
Diabetes. 1994 Aug;43(8):1005-9. doi: 10.2337/diab.43.8.1005.
Glutamic acid decarboxylase antibodies (GADAbs) are being increasingly used in clinical and research programs for the prediction and classification of insulin-dependent diabetes mellitus (IDDM). A number of different assay formats for the measurement of GADAbs have been reported, but the degree of concordance between assays is unknown. In this study, GADAbs were measured on 16 coded sera in 34 assays to examine concordance between GADAb assays and establish the feasibility of an international GADAb standard of measurement unit. The 16 lyophilized coded samples consisted of sera from healthy control subjects (n = 2), IDDM patients (n = 3), a patient with polyendocrine autoimmunity (n = 1), and duplicate dilutions of plasmapheresis serum from a patient with stiff-man syndrome (SMS). A high level of concordance was found in the ranking of GADAb levels (P = 0.99, Friedman's test) in the samples. Thirteen (38%) assays could reproducibly distinguish dilutions of SMS serum and detect GADAbs in all IDDM and polyendocrine autoimmunity sera tested. Although assessed on only four samples, disease specificity was 100% in 29 assays. The majority of assays that immunoprecipitated radiolabeled GAD gave high results for sensitivity and specificity. Enzyme-linked immunosorbent assays and assays using immunofluorescence were generally less sensitive. Several assays, in particular those measuring GAD enzymatic activity immunoprecipitated in fluid phase from rat brain homogenate, showed a prozone-like phenomenon in the SMS dilution curve. Interpolation of results from a standard curve into workshop units resulted in relatively low scatter in samples with lower levels of GADAbs. Hence, the use of an international reference serum to enable comparison of results between laboratories appears feasible.(ABSTRACT TRUNCATED AT 250 WORDS)
谷氨酸脱羧酶抗体(GADAbs)越来越多地用于胰岛素依赖型糖尿病(IDDM)的预测和分类的临床及研究项目中。已经报道了多种用于测量GADAbs的不同检测方法,但各检测方法之间的一致性程度尚不清楚。在本研究中,对16份编码血清进行了34次检测以测量GADAbs,从而检验GADAb检测方法之间的一致性,并确定国际GADAb测量单位标准的可行性。这16份冻干编码样本包括健康对照受试者的血清(n = 2)、IDDM患者的血清(n = 3)、一名多内分泌自身免疫患者的血清(n = 1),以及一名僵人综合征(SMS)患者血浆置换血清的重复稀释样本。在样本中发现GADAb水平的排名具有高度一致性(P = 0.99,Friedman检验)。13种(38%)检测方法能够可重复地区分SMS血清的稀释度,并在所有检测的IDDM和多内分泌自身免疫血清中检测到GADAbs。尽管仅在4个样本上进行了评估,但在29种检测方法中疾病特异性为100%。大多数对放射性标记GAD进行免疫沉淀的检测方法在敏感性和特异性方面给出了较高结果。酶联免疫吸附测定和使用免疫荧光的检测方法通常敏感性较低。几种检测方法,特别是那些测量从大鼠脑匀浆中液相免疫沉淀的GAD酶活性的方法,在SMS稀释曲线中显示出前带样现象。将标准曲线的结果换算为工作单位后,在GADAbs水平较低的样本中散射相对较小。因此,使用国际参考血清以实现实验室间结果的比较似乎是可行的。(摘要截短于250字)